PharmaPoint: Age-Related Macular Degeneration – Global Drug Forecast and Market Analysis to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
There are two clinical forms of age-related macular degeneration (AMD): dry and wet. Currently there are therapies available only for wet AMD. Drugs in late stages of development target the wet AMD segment and the late stage or atrophic form of dry AMD, called geographic atrophy (GA). The global markets are currently overwhelmingly dominated by anti-VEGFs for wAMD, including Lucentis, Eylea, and Avastin, which together accounted for 99.3% of AMD sales. Visudyne, photodynamic therapy (PDT), is used in a minority of patients usually combined with an anti-VEGF.
The AMD pipeline is strong, with two longer-acting anti-VEGF drugs (Novartis/Alcon’s brolucizumab and Allergan’s abicipar pegol) and two add-on therapies (Ohr’s squalamine and Opthea’s OPT-302) in late-stage clinical development (Phase IIb/III) for wet AMD. Four drugs are in the late pipeline for GA, three complement inhibitors (Roche’s lampalizumab, Ophthotech’s Zimura, and Apellis’ APL-2) and a cyto/neuroprotective agent (Allergan’s Brimo DDS), which could launch within the forecast period.
GlobalData estimates the 2016 sales for AMD at approximately $4.9B across the 7MM covered in this report. The AMD market will experience a significant growth during the forecast period at a CAGR of 13.4%, with global sales of $17.3B in 2026. Such rapid growth is due primarily to the introduction of the new therapies for the previously untreatable dry AMD patients with GA, the launch of add-on therapies for wet AMD, and the increasing prevalence of AMD as a result of aging societies.
Scope
Overview of AMD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized AMD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (GA due to dry AMD and wet AMD), forecast from 2016 to 2026.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AMD therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AMD therapy. The most promising candidates in Phase IIb and Phase III developments are profiled.
Analysis of the current and future market competition in the global AMD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
What are the key drivers of significant growth of the AMD market?
How the sales of the current market leader, Bayer’s Eylea, will be affected by the launch of longer-acting anti-VEGF therapies (brolucizumab and abicipar pegol)?
How would physicians fit squalamine and OPT-302 add-on therapies into the wet AMD treatment algorithm and what are their pricing and reimbursement prospects?
What are the market potentials of drugs developed for the treatment of GA associated with dry AMD, and would they fulfil the greatest unmet need in this space?
How will key patent expiries of anti-VEGF therapies and the use of Avastin impact sales of current and launching therapies in wet AMD?
Will there be opportunities remaining after the launch of late pipeline drugs in wet AMD and dry AMD?
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global AMD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AMD therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Genentech
Novartis
Alcon
Regeneron
Bayer
Valeant
Allergan
Ohr
Ophthotech
Apellis
Opthea
Chugai
Pfizer
Santen
PanOptica
SciFluor Life Sciences
Tyrogenex
RXi Pharmaceuticals
Janssen
Astellas Pharma
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.